JP7204484B2 - T細胞受容体 - Google Patents

T細胞受容体 Download PDF

Info

Publication number
JP7204484B2
JP7204484B2 JP2018552775A JP2018552775A JP7204484B2 JP 7204484 B2 JP7204484 B2 JP 7204484B2 JP 2018552775 A JP2018552775 A JP 2018552775A JP 2018552775 A JP2018552775 A JP 2018552775A JP 7204484 B2 JP7204484 B2 JP 7204484B2
Authority
JP
Japan
Prior art keywords
tcr
amino acid
sequence
seq
acid residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018552775A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019516356A (ja
Inventor
トリブル,ニコラス
ローレンス,ウィリアム
バッグ,エリノア
Original Assignee
アダプティミューン・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58536983&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7204484(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アダプティミューン・リミテッド filed Critical アダプティミューン・リミテッド
Publication of JP2019516356A publication Critical patent/JP2019516356A/ja
Priority to JP2022084419A priority Critical patent/JP7572399B2/ja
Application granted granted Critical
Publication of JP7204484B2 publication Critical patent/JP7204484B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2018552775A 2016-04-08 2017-04-10 T細胞受容体 Active JP7204484B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022084419A JP7572399B2 (ja) 2016-04-08 2022-05-24 T細胞受容体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1606156.6 2016-04-08
GB201606156 2016-04-08
PCT/EP2017/058578 WO2017174823A1 (en) 2016-04-08 2017-04-10 T cell receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022084419A Division JP7572399B2 (ja) 2016-04-08 2022-05-24 T細胞受容体

Publications (2)

Publication Number Publication Date
JP2019516356A JP2019516356A (ja) 2019-06-20
JP7204484B2 true JP7204484B2 (ja) 2023-01-16

Family

ID=58536983

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018552775A Active JP7204484B2 (ja) 2016-04-08 2017-04-10 T細胞受容体
JP2022084419A Active JP7572399B2 (ja) 2016-04-08 2022-05-24 T細胞受容体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022084419A Active JP7572399B2 (ja) 2016-04-08 2022-05-24 T細胞受容体

Country Status (15)

Country Link
US (3) US20190144521A1 (cg-RX-API-DMAC7.html)
EP (2) EP3925972A1 (cg-RX-API-DMAC7.html)
JP (2) JP7204484B2 (cg-RX-API-DMAC7.html)
KR (1) KR20190065189A (cg-RX-API-DMAC7.html)
CN (2) CN116239669A (cg-RX-API-DMAC7.html)
AU (2) AU2017248121B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018070637A2 (cg-RX-API-DMAC7.html)
CA (1) CA3020555A1 (cg-RX-API-DMAC7.html)
ES (1) ES2788188T5 (cg-RX-API-DMAC7.html)
IL (1) IL262124A (cg-RX-API-DMAC7.html)
MX (1) MX389173B (cg-RX-API-DMAC7.html)
RU (1) RU2018138837A (cg-RX-API-DMAC7.html)
SG (1) SG11201808750PA (cg-RX-API-DMAC7.html)
WO (1) WO2017174823A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201806862B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022122913A (ja) * 2016-04-08 2022-08-23 アダプティミューン・リミテッド T細胞受容体

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
MA50819A (fr) 2014-12-23 2021-04-07 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
MX2018012265A (es) * 2016-04-08 2019-02-07 Adaptimmune Ltd Receptores de celulas t.
MX395611B (es) 2016-04-08 2025-03-25 Adaptimmune Ltd Receptores de celulas t.
WO2019069125A1 (en) 2017-10-06 2019-04-11 Oslo Universitetssykehus Hf CHIMERIC ANTIGEN RECEPTORS
JPWO2019151392A1 (ja) * 2018-01-31 2021-02-04 国立大学法人東北大学 抗原特異的mhc発現調節法
KR102892744B1 (ko) * 2018-04-19 2025-11-28 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Mage-b2 특이성을 갖는 t 세포 수용체 및 이의 용도
GB201819540D0 (en) * 2018-11-30 2019-01-16 Adaptimmune Ltd T cell modification
CN110172091B (zh) * 2019-04-28 2020-04-03 天津亨佳生物科技发展有限公司 一种针对egfr l858r基因突变的特异性t细胞受体及其应用
MX2021015946A (es) * 2019-06-18 2022-04-18 Regeneron Pharma Receptores de linfocitos t de mage-a4 y métodos de uso de estos.
CN114245807B (zh) 2019-06-25 2025-05-02 吉利德科学公司 Flt3l-fc融合蛋白和使用方法
CN114555791B (zh) 2019-08-13 2026-07-14 伦敦国王学院 Il-1超家族时空限制性活性细胞因子铠装的免疫应答细胞
US12480958B2 (en) 2019-08-13 2025-11-25 Immatics Biotechnologies Gmbh Method for the characterization of peptide:MHC binding polypeptides
TWI890283B (zh) 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
WO2021236638A1 (en) 2020-05-19 2021-11-25 Amgen Inc. Mageb2 binding constructs
CN111647069B (zh) * 2020-06-17 2022-06-21 深圳豪石生物科技有限公司 一种改进的tcr及其应用
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
WO2022140321A2 (en) * 2020-12-22 2022-06-30 Amgen Inc. Mage-b2-specific t-cell receptors
EP4304726A1 (en) 2021-03-09 2024-01-17 CDR-Life AG Mage-a4 peptide-mhc antigen binding proteins
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
EP4423078A1 (en) 2021-10-28 2024-09-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
PE20241186A1 (es) 2021-10-29 2024-06-03 Gilead Sciences Inc Compuestos de cd73
US20240124412A1 (en) 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CN118488948A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
CA3248911A1 (en) 2022-01-28 2023-08-03 Gilead Sciences, Inc. POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS
PL4245756T3 (pl) 2022-03-17 2025-02-17 Gilead Sciences, Inc. Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
CN116836261A (zh) * 2022-03-24 2023-10-03 香雪生命科学技术(广东)有限公司 一种识别mage-a4抗原的高亲和力tcr及其序列和应用
EP4511127A1 (en) 2022-04-21 2025-02-26 Gilead Sciences, Inc. Kras g12d modulating compounds
CN117106060A (zh) * 2022-05-17 2023-11-24 香雪生命科学技术(广东)有限公司 一种识别mage的高亲和力t细胞受体及其应用
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
EP4587046A1 (en) 2022-09-14 2025-07-23 CDR-Life AG Mage-a4 peptide dual t cell engagers
EP4638436A1 (en) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
PE20260121A1 (es) 2023-04-21 2026-01-16 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
JP2026522894A (ja) 2023-06-30 2026-07-09 ギリアード サイエンシーズ, インコーポレイテッド Kras調節化合物
CN121568935A (zh) 2023-07-26 2026-02-24 吉利德科学公司 Parp7抑制剂
AU2024297978A1 (en) 2023-07-26 2026-02-05 Gilead Sciences, Inc. Parp7 inhibitors
EP4750807A1 (en) * 2023-07-27 2026-06-03 Immatics Biotechnologies GmbH Novel t cell receptors targeting melanoma-associated antigen (mage) b2 and immune therapy using the same
EP4750806A1 (en) * 2023-07-27 2026-06-03 Immatics Biotechnologies GmbH Antigen binding proteins against mageb2
EP4774280A1 (en) 2023-09-08 2026-07-15 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20260098049A1 (en) 2024-08-12 2026-04-09 Gilead Sciences, Inc. Kras modulating compounds
US20260130893A1 (en) 2024-10-21 2026-05-14 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2026136515A1 (en) 2024-12-19 2026-06-25 Gilead Sciences, Inc. Parp7 inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003518911A (ja) 1998-10-02 2003-06-17 ルートヴィッヒ・インスティチュート・フォー・キャンサー・リサーチ 新規の方法により単離される、腫瘍抗原及びctlクローン
JP2015163067A (ja) 2015-03-04 2015-09-10 ヴァクソン バイオテックVaxon Biotech 共有hla−b*0702エピトープの同定、最適化および免疫療法のための使用
JP2019513383A (ja) 2016-04-08 2019-05-30 アダプティミューン・リミテッド T細胞受容体
JP2019516357A (ja) 2016-04-08 2019-06-20 イムノコア リミテッド T細胞レセプター
JP2019516355A (ja) 2016-04-08 2019-06-20 アダプティミューン・リミテッド T細胞受容体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596536B1 (en) * 1991-02-08 2003-07-22 Aventis Pharma S.A. Nucleotide sequences coding for variable regions of the alpha chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses
AU5992999A (en) 1998-10-02 2000-04-26 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
US20050053918A1 (en) 2001-05-16 2005-03-10 Technion Research & Development Foundation Ltd. Method of identifying peptides capable of binding to MHC molecules, peptides identified thereby and their uses
US6867283B2 (en) * 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
PT1421115E (pt) 2001-08-31 2005-07-29 Avidex Ltd Receptor de celulas t soluvel
GB0304068D0 (en) * 2003-02-22 2003-03-26 Avidex Ltd Substances
WO2010114129A1 (ja) * 2009-04-03 2010-10-07 国立大学法人愛媛大学 T細胞レセプター及び該レセプターをコードする核酸
US10024868B2 (en) 2009-06-09 2018-07-17 Vaxon Biotech Identification, optimization and use of shared HLA-B*0702 epitopes for immunotherapy
ES2635335T3 (es) 2010-09-20 2017-10-03 Biontech Cell & Gene Therapies Gmbh Receptores de células T específicos de antígeno y epítopos de células T
SG11201400521PA (en) * 2011-10-14 2014-08-28 Teva Pharmaceuticals Australia Pty Ltd ANTIBODIES TO CD1d
CA2912389C (en) * 2013-06-10 2020-01-28 The General Hospital Corporation D/B/A Massachusetts General Hospital Methods and compositions for reducing immunosupression by tumor cells
KR20190065189A (ko) * 2016-04-08 2019-06-11 어댑티뮨 리미티드 T 세포 수용체

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003518911A (ja) 1998-10-02 2003-06-17 ルートヴィッヒ・インスティチュート・フォー・キャンサー・リサーチ 新規の方法により単離される、腫瘍抗原及びctlクローン
JP2015163067A (ja) 2015-03-04 2015-09-10 ヴァクソン バイオテックVaxon Biotech 共有hla−b*0702エピトープの同定、最適化および免疫療法のための使用
JP2019513383A (ja) 2016-04-08 2019-05-30 アダプティミューン・リミテッド T細胞受容体
JP2019516357A (ja) 2016-04-08 2019-06-20 イムノコア リミテッド T細胞レセプター
JP2019516355A (ja) 2016-04-08 2019-06-20 アダプティミューン・リミテッド T細胞受容体

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022122913A (ja) * 2016-04-08 2022-08-23 アダプティミューン・リミテッド T細胞受容体
JP7572399B2 (ja) 2016-04-08 2024-10-23 アダプティミューン・リミテッド T細胞受容体

Also Published As

Publication number Publication date
JP2022122913A (ja) 2022-08-23
US20220025013A1 (en) 2022-01-27
NZ747962A (en) 2024-12-20
US11753456B2 (en) 2023-09-12
AU2017248121A1 (en) 2018-11-22
RU2018138837A3 (cg-RX-API-DMAC7.html) 2020-07-30
RU2018138837A (ru) 2020-05-12
CN109476724B (zh) 2023-04-04
AU2022256182A1 (en) 2022-11-24
MX2018012268A (es) 2019-02-07
ES2788188T3 (es) 2020-10-20
WO2017174823A1 (en) 2017-10-12
CN116239669A (zh) 2023-06-09
US20190144521A1 (en) 2019-05-16
SG11201808750PA (en) 2018-11-29
KR20190065189A (ko) 2019-06-11
BR112018070637A2 (pt) 2019-02-05
EP3440104B1 (en) 2020-03-11
EP3440104A1 (en) 2019-02-13
IL262124A (en) 2018-11-29
WO2017174823A4 (en) 2017-12-07
US12180261B2 (en) 2024-12-31
AU2017248121B2 (en) 2022-07-21
JP7572399B2 (ja) 2024-10-23
MX389173B (es) 2025-03-20
ZA201806862B (en) 2021-04-28
CA3020555A1 (en) 2017-10-12
ES2788188T5 (es) 2023-10-24
US20240010702A1 (en) 2024-01-11
EP3440104B2 (en) 2023-06-14
EP3925972A1 (en) 2021-12-22
JP2019516356A (ja) 2019-06-20
CN109476724A (zh) 2019-03-15

Similar Documents

Publication Publication Date Title
JP7577149B2 (ja) T細胞受容体
JP7437452B2 (ja) T細胞受容体
JP7572399B2 (ja) T細胞受容体
JP6751391B2 (ja) T細胞受容体
HK40066361A (en) T cell receptors
HK40073110A (en) T cell receptors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200401

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210825

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220524

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220524

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220603

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220627

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221206

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221228

R150 Certificate of patent or registration of utility model

Ref document number: 7204484

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150